Insight, China's Pharmaceutical Industry

Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced a strategic collaboration with Antengene Corporation Limited...

Company

AbbVie Invests $380M in Illinois API Manufacturing – AI‑Enabled Facilities for Neuroscience and Obesity Drugs

Fineline Cube Feb 25, 2026

AbbVie (NYSE: ABBV) announced a USD 380 million investment to build two new active pharmaceutical ingredient (API) manufacturing...

Company Drug

Novo Nordisk to Cut Semaglutide List Prices by 35‑50% – Wegovy, Ozempic, Rybelsus Standardized at $675/Month

Fineline Cube Feb 25, 2026

Novo Nordisk (NYSE: NVO) announced that, effective January 1, 2027, it will lower Wholesale Acquisition Cost (list prices)...

Company Deals

Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development

Fineline Cube Feb 25, 2026

Dartsbio Pharmaceuticals announced an exclusive licensing agreement with Slate Medicines, Inc., a US‑based emerging biopharmaceutical...

Company Deals

Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint

Fineline Cube Feb 25, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced an exclusive license agreement with Abbott for the commercialization...

Company Drug

SinoMab’s First‑in‑Class IL‑25R Antibody SM17 Wins NMPA IND Approval – Novel IBD Therapy Enters Clinic

Fineline Cube Feb 25, 2026

SinoMab BioScience Limited (HKG: 3681) announced that China’s National Medical Products Administration (NMPA) has approved the...

Company Drug

Hengrui’s ANGPTL3 Antibody SHR-1918 NDA Accepted by NMPA – Priority Review for Rare Disease HoFH

Fineline Cube Feb 25, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Pharscin Pharma’s PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval – First Class 1.1 Innovative Drug Enters Clinic

Fineline Cube Feb 25, 2026

Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE: 002907) announced that China’s National Medical Products Administration (NMPA) has...

Company Drug

CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion – MCV4 Now Covers Children Up to 6 Years

Fineline Cube Feb 25, 2026

CanSino Biologics (HKG: 6185) announced that China’s National Medical Products Administration (NMPA) has approved a supplementary...

Company Deals Digital

Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets – AI‑Driven Multi‑Omics Analysis

Fineline Cube Feb 25, 2026

Insilico Medicine (HKG: 3696) announced a collaboration agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to...

Company Deals

YolTech Partners with XtalPi to Build AI‑Driven mRNA and CAR‑T Screening Platform – Closed‑Loop Dry‑Wet Lab Integration

Fineline Cube Feb 24, 2026

YolTech Therapeutics, a China‑based mRNA therapy and gene therapy developer, announced a strategic partnership with...

Company

J&J Invests $1B+ in Pennsylvania Cell Therapy Facility – Expands Manufacturing for Cancer and Neurology Pipeline

Fineline Cube Feb 24, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced a more than USD 1 billion investment to build a next‑generation...

Company Deals

Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal – Expands Global RNAi Partnership

Fineline Cube Feb 24, 2026

Frontier Biotechnologies Inc. (SHA: 688221) announced a licensing agreement with GlaxoSmithKline (GSK, NYSE: GSK), granting the UK...

Company Drug

J&J’s RYBREVANT SC Dosing Approved by EC – Expands Subcutaneous Options Across All NSCLC Indications

Fineline Cube Feb 24, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved an extension...

Company Deals

Harbour BioMed Licenses HBM4003 to Solstice Oncology in $1.2B+ Deal – Expands Global Footprint for CTLA‑4 Asset

Fineline Cube Feb 24, 2026

Harbour BioMed (HKG: 2142) announced a licensing agreement and equity partnership with Solstice Oncology, a clinical‑stage...

Company Drug

CSPC Pharmaceutical Wins NMPA Approval for Phase II Study of SYS6023 HER3 ADC in Metastatic Breast Cancer

Fineline Cube Feb 24, 2026

CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that China’s National Medical Products Administration (NMPA) has granted...

Others

Trinomab’s Retavibart NDA Accepted by NMPA – First Long‑Acting RSV mAb for Infant Protection in China

Fineline Cube Feb 24, 2026

Zhuhai Trinomab Biopharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has accepted...

Company Drug

Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit

Fineline Cube Feb 24, 2026

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that its iza‑bren, a first‑in‑class EGFR×HER3 bispecific antibody‑drug...

Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026

The U.S. Food and Drug Administration (FDA) released a draft guidance titled “Considerations for the...

Company Deals

Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel

Fineline Cube Feb 24, 2026

Gilead Sciences Inc. (NASDAQ: GILD) announced a definitive agreement to acquire Arcellx Inc. (NASDAQ: ACLX) for USD 115.00...

Insight, China's Pharmaceutical Industry

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution

Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor

AbbVie Invests $380M in Illinois API Manufacturing – AI‑Enabled Facilities for Neuroscience and Obesity Drugs

Novo Nordisk to Cut Semaglutide List Prices by 35‑50% – Wegovy, Ozempic, Rybelsus Standardized at $675/Month

Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development

Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint

SinoMab’s First‑in‑Class IL‑25R Antibody SM17 Wins NMPA IND Approval – Novel IBD Therapy Enters Clinic

Hengrui’s ANGPTL3 Antibody SHR-1918 NDA Accepted by NMPA – Priority Review for Rare Disease HoFH

Pharscin Pharma’s PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval – First Class 1.1 Innovative Drug Enters Clinic

CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion – MCV4 Now Covers Children Up to 6 Years

Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets – AI‑Driven Multi‑Omics Analysis

YolTech Partners with XtalPi to Build AI‑Driven mRNA and CAR‑T Screening Platform – Closed‑Loop Dry‑Wet Lab Integration

J&J Invests $1B+ in Pennsylvania Cell Therapy Facility – Expands Manufacturing for Cancer and Neurology Pipeline

Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal – Expands Global RNAi Partnership

J&J’s RYBREVANT SC Dosing Approved by EC – Expands Subcutaneous Options Across All NSCLC Indications

Harbour BioMed Licenses HBM4003 to Solstice Oncology in $1.2B+ Deal – Expands Global Footprint for CTLA‑4 Asset

CSPC Pharmaceutical Wins NMPA Approval for Phase II Study of SYS6023 HER3 ADC in Metastatic Breast Cancer

Trinomab’s Retavibart NDA Accepted by NMPA – First Long‑Acting RSV mAb for Infant Protection in China

Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel

You Missed

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways